Sporadic and infectious human prion diseases

Cold Spring Harbor Perspectives in Medicine

Volumn 7, Issue 1, 2017, Pages

  Will, Robert G ^a   Ironside, James W ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD TRANSFUSION; BRAIN SCINTISCANNING; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE TRANSMISSION; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAM; HUMAN; IATROGENIC CREUTZFELDT JAKOB DISEASE; INCUBATION TIME; KURU; MORTALITY RATE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRION; RISK FACTOR; SPATIOTEMPORAL ANALYSIS; SPORADIC CREUTZFELDT JAKOB DISEASE; VARIANT CREUTZFELDT JAKOB DISEASE; ANIMAL; BRAIN; CLASSIFICATION; DIAGNOSTIC IMAGING; EUROPE; GENETICS; MOUSE; PRION DISEASES;

PRION PROTEIN;

ANIMALS; BRAIN; EUROPE; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; PRION DISEASES; PRION PROTEINS;

EID: 85008698242     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a024364     Document Type: Article

References (97)

1. Alcalde-Cabero E, Almazán-Isla J, Brandel JP, Breithaupt M, Catarino J, Collins S, Haybäck J, Höftberger R, Kahana E, Kovacs GG, et al. 2012. Health professionals and risk of sporadic Creutzfeldt-Jakob disease, 1965 to 2010. Eurosurveillance 17: 1-10.
2. Barbot C, Castro L, Oliveira C, Carpenter C. 2010. Variant Creutzfeldt-Jakob disease: The first confirmed cases from Portugal shows early onset, long duration and unusual pathology. J Neurol Neurosurg Psychiatry 81: 112-115.
3. Binelli S, Agazzi P, Giaccone G, Will RG, Bugiani O, Franceschetti S, Tagliavini F. 2006. Periodic electroencephalogram complexes in a patient with variant Creutzfeldt-Jakob disease. Ann Neurol 59: 423-427.
4. Bishop MT, Ritchie DL, Will RG, Ironside JW, Head MW, Thomson V, Bruce M, Manson JC. 2008. No major change in vCJD agent strain after secondary transmission via blood transfusion. PLoS ONE 3: 1-6.
5. Bishop MT, Will RG, Manson JC. 2010. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci 107: 12005-12010.
6. Bishop MT, Diack AB, Ritchie DL, Ironside JW, Will RG, Manson JC. 2013. Prion infectivity in the spleen of a PRNP heterozygous individual with subclinical variant Creutzfeldt-Jakob disease. Brain 136: 1139-1145.
7. Boelle PY, Thomas G, Valleron AJ, Cesbron JY, Will R. 2003. Modelling the epidemic of variant Creutzfeldt-Jakob disease in the UK based on age characteristics: Updated, detailed analysis. Stat Methods Med Res 12: 221-233.
8. Brandel JP, Preece M, Brown P, Croes E, Laplanche JL, Agid Y, Will R, Alperovitch A. 2003. Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet 362: 128-130.
9. Brandner S, Whitfield J, Boone K, Puwa A, O’Malley C, Linehan JM, Joiner S, Scaravilli F, Calder I, Alpers M, et al. 2008. Central and peripheral pathology of kuru: Pathological analysis of a recent case and comparison with other forms of human prion disease. Phil Trans R Soc Lond B Biol Sci 363: 3755-3763.
10. Brown P, Rodgers-Johnson P, Cathala F, Gibbs CJ Jr, Gajdusek DC. 1984. Creutzfeldt-Jakob disease of long duration: Clinicopathological characteristics, transmissibility, and differential diagnosis. Ann Neurol 16: 295-304.
11. Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I, Fletcher A, Will RG, Pocchiari M, Cashman NR, et al. 2000. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 55: 1075-1081.
12. Brown P, Brandel JP, Sato T, Nakamura Y, Mackenzie J, Will RG, Ladogana A, Pocchiari M, Leschek EW, Schonberger LB. 2012. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 18: 901-907.
13. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, et al. 1997. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. Nature 389: 498-501.
14. Bruce ME, McConnell I, Will RG, Ironside JW. 2001. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 358: 208-209.
15. Chohan G. 2013. Correlative study of the clinical, pathological and biochemical features of sporadic CJD. MDthesis, University of Edinburgh, UK.
16. Colby DW, Prusiner SB. 2011. Prions. Cold Spring Harb Perspect Biol 3: a006833.
17. Collie DA, Summers DM, Sellar RJ, Ironside JW, Cooper S, Zeidler M, Knight R, Will RG. 2003. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. Am J Neuroradiol 24: 1560-1569.
18. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. 1996. Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature 383: 685-690.
19. Collinge J, Whitfield J, McKintosh E, Beck J, Mead S, Thomas DJ, Alpers MP. 2006. Kuru in the 21st century-An acquired human prion disease with very long incubation periods. Lancet 367: 2068-2074.
20. Collinge J, Whitfield J, McKintosh E, Frosh A, Mead S, Hill AF, Brandner S, Thomas D, Alpers MP. 2008. A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Phil Trans R Soc Lond B Biol Sci 363: 3725-3739.
21. Cooper JD, Bird SM. 2002. UK dietary exposure to BSE in beef mechanically recovered meat: By birth cohort and gender. J Cancer Epidemiol Prev 7: 59-70.
22. Cooper SA, Heath CA, Will RG, Knight RS. 2005. Visual loss at onset of sporadic Creutzfeldt-Jakob disease: Making sense of the "Heidenhain variant." J Neurol Neurosurg Psychiatry 76: 156.
23. Cooper SA, Murray KL, Heath CA, Will RG, Knight RS. 2006. Sporadic Creutzfeldt-Jakob disease with cerebellar ataxia at onset in the United Kingdom. J Neurol Neurosurg Psychiatry 77: 1273-1275.
24. Cousens SN, Zeidler M, Esmonde TF, De Silva R, Wilesmith JW, Smith PG, Will RG. 1997. Sporadic Creutzfeldt-Jakob disease in the United Kingdom: Analysis of epidemiological surveillance data for 1970-96. BMJ 315: 389-395.
25. Creutzfeldt HG. 1920. On a particular focal disease of the central nervous system (preliminary communication). Z Ges Neurol Psychiat 57: 1-18.
26. de Pedro Cuesta J, Mahillo-Fernández I, Rábano A, Calero M, Cruz M, Siden A, Laursen H, Falkenhorst G, Mølbak K; EUROSURGYCJD Research Group. 2011. Nosocomial transmission of sporadic Creutzfeldt-Jakob disease: Results from a risk-based assessment of surgical interventions. J Neurol Neurosurg Psychiatry 82: 204-212.
27. de Pedro Cuesta J, Ruiz Tovar M, Ward H, Calero M, Smith A, Verduras CA, Pocchiari M, Turner ML, Forland F, Palm D, et al. 2012. Sensitivity to biases of case-control studies on medical procedures, particularly surgery and blood transfusion, and risk of Creutzfeldt-Jakob disease. Neuroepidemiology 39: 1-18.
28. de Pedro Cuesta J, Mahillo-Fernández I, Calero M, Rábano A, Cruz M, Siden A, Martinez-Martin P, Laursen H, Ruiz-Tovar M, Mølbak K, et al. 2014. Towards an age-dependent transmission model of acquired and sporadic Creutzfeldt-Jakob disease. PLoS ONE 9: e109412.
29. Diack AB, Ritchie DL, Peden AH, Brown D, Boyle A, Morabito L, Maclennan D, Burgoyne P, Jansen C, Knight RS, et al. 2014. Variably protease-sensitive prionopathy, a unique prion variant with inefficient transmission properties. Emerg Infect Dis 20: 1969-1979.
30. Dorsey K, Zou S, Schonberger LB, Sullivan M, Kessler D, Notari E IV, Fang CT, Dodd RY. 2009. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study. Transfusion 49: 977-984.
31. Edgeworth JA, Farmer M, Sicilia A, Tavares P, Beck J, Campbell T, Lowe J, Mead S, Rudge P, Collinge J, et al. 2011. Detection of prion infection in variant Creutzfeldt-Jakob disease: A blood-based assay. Lancet 377: 487-493.
32. Gajdusek DC, Gibbs CJ Jr, Alpers M. 1966. Experimental transmission of a kuru-like syndrome in chimpanzees. Nature 209: 794-796.
33. Gambetti P, Dong Z, Yuan J, Xiao X, Zheng M, Alshekhlee A, Castellani R, Cohen M, Barria MA, Gonzalez-Romero D, et al. 2008. A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol 63: 697-708.
34. Garske T, Ghani AC. 2010. Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK. PLoS ONE 5: e15626.
35. Gibbs CJ, Gajdusek DC, Asher DM, Alpers HP, Beck E, Daniel PM, Matthews WB. 1968. Creutzfeldt-Jakob disease (spongiform encephalopathy): Transmission to the chimpanzee. Science 161: 388-389.
36. Gill ON, Spencer Y, Richard-Loendt A, Kelly C, Dabaghian R, Boyes L, Linehan J, Simmons M, Webb P, Bellerby P, et al. 2013. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: Large scale survey. BMJ 347: f5675.
37. Glatzel M, Abela E, Maissen M, Aguzzi A. 2003. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. New Engl J Med 349: 1812-1820.
38. Green AJ, Thompson EJ, Stewart GE, Zeidler M, Mackenzie JM, Macleod MA, Ironside JW, Will RG, Knight RS. 2001. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 70: 744-748.
39. Green A, Sanchez-Juan P, Ladogana A, Cuadrado-Corrales N, Sánchez-Valle R, Mitrová E, Stoeck K, Sklaviadis T, Kulczycki J, Heinemenn U, et al. 2007. CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies. Eur J Neurol 14: 121-124.
40. Hadlow WJ. 1959. Scrapie and kuru. Lancet 2: 289-290.
41. Head MW, Ironside JW. 2012. Review: Creutzfeldt-Jakob disease: Prion protein type, disease phenotype and agent strain. Neuropathol Appl Neurobiol 38: 296-310.
42. Head MW, Ritchie D, Smith N, McLoughlin V, Nailon W, Samad S, Masson S, Bishop M, McCardle L, Ironside JW. 2004. Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: An immunohistological, quantitative and biochemical study. Am J Pathol 164: 143-153.
43. Head MW, Yull HM, Ritchie DL, Langeveld JP, Fletcher NA, Knight RS, Ironside JW. 2013. Variably protease-sensitive prionopathy in the UK: A retrospective review 1991-2008. Brain 136: 1102-1115.
44. Heath CA, Will RG. 2008. Clinical aspects of variant Creutzfeldt-Jakob disease. In Handbook of clinical neurology, Vol. 89 (3rd series) (ed. Duyckaerts C), pp. 765-778. Elsevier, Amsterdam.
45. Heath CA, Barker RA, Esmonde TF, Harvey P, Trend P, Head MW, Smith C, Bell JE, Ironside JW, Will RG, et al. 2006. Dura mater-associated Creutzfeldt-Jakob disease: Experience from surveillance in the UK. J Neurol Neurosurg Psychiatry 77: 880-882.
46. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. 2006. Creutzfeldt-Jakob disease and blood transfusion: Results of the UK Transfusion Medicine Epidemiology Review study. Vox Sanguinis 91: 221-230.
47. Hill AF, Desbruslais M, Joiner S, Sidle KA, Gowland I, Collinge J. 1997a. The same prion strain causes vCJD and BSE. Nature 389: 448-450.
48. Hill AF, Zeidler M, Ironside J, Collinge J. 1997b. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 349: 99-100.
49. Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor MN, Thomas DJ, Frosh A, Tolley N, Bell JE, Spencer M, et al. 1999. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 353: 183-189.
50. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, Penney M, Hegazy D, Ironside JW. 2004. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 203: 733-739.
51. Ironside JW, Ritchie DL, Head MW. 2005. Phenotypic variability in human prion diseases. Neuropathol Appl Neurobiol 31: 565-579.
52. Ironside JW, Bishop MT, Connolly K, Hegazy D, Lowrie S, Le Grice M, Ritchie DL, McCardle LM, Hilton DA. 2006. Variant Creutzfeldt-Jakob disease: Prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 332: 1186-1188.
53. Ironside JW, Ghetti B, Head MW, Piccardo P, Will RG. 2008. Prion diseases. In Greenfield’s neuropathology, 8th ed., pp. 1197-1273. Hodder Arnold, London, pp. 1197-1273.
54. Jakob A. 1921. On a disease of the central nervous system clinically related to multiple sclerosis (spastic pseudo sclerosis) with remarkable anatomical findings. Medizinische Klinik 13: 372-376.
55. Jansen C, Head MW, Rozemuller AJ, Ironside JW. 2009. Panencephalopathic Creuzfeldt-Jakob disease in the Netherlands and the UK: Clinical and pathological characteristics of nine patients. Neuropathol Appl Neurobiol 35: 272-282.
56. Jaumuktane Z, Mead S, Ellis M, Wadsworth JD, Nicoll AJ, Kenny J, Launchbury F, Linehan J, Richard-Loendt A, Walker AS, et al. Evidence for human transmission of amyloid-b pathology and cerebral amyloid angiopathy. 2015. Nature 525: 247-250.
57. Kovacs GG, Peden A, Weis S, Höftberger R, Berghoff AS, Yull H, Ströbel T, Koppi S, Katzenschlager R, Langenscheidt D, et al. 2013. Rapidly progressive dementiawith thalamic ringeneration and peculiar cortical prion protein immunoreactivity, but absence of proteinase K resistant PrP: A new disease entity? Acta Neuropathol Commun 1: 72.
58. Lacroux C, Comoy E, Moudjou M, Perret-Liaudet A, Lugan S, Litaise C, Simmons H, Jas-Duval C, Lantier I, Béringue V, et al. 2014. Preclinical detection of variant CJD and BSE prions in blood. PLoS ONE 10: e1004202.
59. Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, Klug GM, Sutcliffe T, Giulivi A, Alperovitch A, et al. 2005. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology 64: 1586-1591.
60. Liberski PP, Sikorska B, Lindenbaum S, Goldfarb LG, McLean C, Hainfellner JA, Brown P. 2012. Kuru: Genes, cannibals and neuropathology. J Neuropathol Exp Neurol 71: 92-103.
61. McGuire LI, Peden AH, Orrú CD, Wilham JM, Appleford NE, Mallinson G, Andrews M, Head MW, Caughey B, Will RG, et al. 2012. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol 72: 278-285.
62. McNaughton HK, Will RG. 1997. Creutzfeldt-Jakob disease presenting acutely as stroke: An analysis of 30 cases. Neurol Infect Epidemiol 2: 19-24.
63. Meissner B, Kallenberg K, Sanchez-Juan P, Collie D, Summers DM, Almonti S, Collins SJ, Smith P, Cras P, Jansen GH, et al. 2009a. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology 72: 1994-2001.
64. Meissner B, Kallenberg K, Sanchez-Juan P, Ramljak S, Krasnianski A, Heinemenn U, Eigenbrod S, Gelpi E, Barsic B, Kretzschmar HA, et al. 2009b. MRIand clinical syndrome in dura mater-related Creutzfeldt-Jakob disease. JNeurol 256: 355-363.
65. Moda F, Suardi S, Di Fede G, Indaco A, Limido L, Vimercati C, Ruggerone M, Campagnani I, Langeveld J, Terruzzi A, et al. 2012. MM2-thalamic Creutzfeldt-Jakob disease: Neuropathological, biochemical and transmission studies identify a distinctive prion strain. Brain Pathol 22: 662-669.
66. Moda F, Gambetti P, Notari S, Concha-Marambio L, Catania M, Park KW, Mederna E, Suardi S, Haik S, Brandel JP, et al. 2014. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. New Engl J Med 371: 530-539.
67. Neumann MA, Gajdusek DC, Zigas V. 1964. Neuropathologic findings in exotic neurologic disorders among natives of the highlands of New Guinea. J Neuropathol Exp Neurol 23: 486-507.
68. Notari S, Moleres FJ, Hunter SB, Belay ED, Schonberger LB, Cali I, Parchi P, Shieh WJ, Brown P, Zaki S, et al. 2010. Multiorgan detection and characterization of proteaseresistant prion protein in a case of variant CJD examined in the United States. PLoS ONE 5: e8765.
69. Notari S, Xiao X, Espinosa JC, Cohen Y, Quing L, Aguilar-Calvo P, Kofskey D, Cali I, Cracco L, Kong Q, et al. 2014. Transmission characteristics of variably protease-sensitive prionopathy. Emerg Infect Dis 12: 2006-2014.
70. Orrú CD, Bongianni M, Tonoli G, Ferrari S, Hughson AG, Groveman BR, Fiorini M, Pocchiari M, Monaco S, Caughey B, et al. 2014. A test for Creutzfeldt-Jakob disease using nasal brushings. New Engl J Med 371: 519-529.
71. Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, Farlow M, Dickson DW, Sima AA, Trojanowski JQ, et al. 1996. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 39: 767-778.
72. Parchi P, Capellari S, Chen SG, Petersen RB, Gambetti P, Knopp N, Brown P, Kitamoto T, Tateishi J, Giese A, et al. 1997. Typing prion isoforms. Nature 386: 232-234.
73. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, et al. 1999. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46: 224-233.
74. Parchi P, Strammiello R, Notari S, Giese A, Langeveld JP, Ladogana A, Zerr I, Roncaroli F, Cras P, Ghetti B, et al. 2009. Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and cooccurrence of PrPSc types: An updated classification. Acta Neuropathol 118: 659-671.
75. Peden AH, Head MW, Ritchie DL, Bell JE, IronsideJW. 2004. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364: 527-529.
76. Peden AH, Ritchie DL, Uddin HP, Daen AF, Schiller KA, Head MW, Ironside JW. 2007. Abnormal prion protein in the pituitary in sporadic and variant Creutzfeldt-Jakob disease. J Gen Virol 88: 1068-1072.
77. Peden A, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Keeling DM, Millar CM, Hill FG, Ironside JW. 2010. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 16: 296-304.
78. Prusiner SB. 2013. Biology and genetics of prions causing neuroringeneration. Annu Rev Genet 47: 601-623.
79. Puopolo M, Ladogana A, Vetrugno V, Pocchiari M. 2011. Transmission of sporadic Creutzfeldt-Jakob disease by blood transfusion: Risk factor or possible biases. Transfusion 51: 1556-1566.
80. Rudge P, Jaumuktane Z, Adlard P, Bjurstrom N, Caine D, Lowe J, Norsworthy P, Hummerich H, Druyeh R, Wadsworth JDF, et al. 2015. Iatrogenic CJD due to pituitaryderived growth hormonewith genetically determined incubation times of up to 40 years. Brain 138: 3386-3399.
81. Scott MR, Will RG, Ironside J, Nguyen HO, Tremblay P, DeArmond SJ, Prusiner SB. 1999. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci 96: 15137-15142.
82. St Rose SG, Hunter N, Matthews L, Foster JD, Chase-Topping ME, Kruuk LE, Shaw DJ, Rhind SM, Will RG, Woolhouse ME. 2006. Comparative evidence for a link between Peyer’s patch development and susceptiblity to transmissible spongiform encephalopathies. BMC Infect Dis 6: 5.
83. Turner M. 2006. Transfusion safety with regards to prions: Ethical, legal and societal considerations. Transfus Clin Biol 13: 317-319.
84. Valleron AJ, Boelle PY, Will R, Cesbron JY. 2001. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science 294: 1726-1728.
85. Wadsworth JD, Joiner S, Linehan J, Desbruslais M, Fox K, Cooper S, Cronier S, Asante EA, Mead S, Brandner S, et al. 2008. Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc Natl Acad Sci 105: 3885-3890.
86. Ward HJ, Everington D, Cousens SN, Smith-Bathgate B, Leitch M, Cooper S, Heath C, Knight RS, Will RG. 2006. Risk factors for variant Creutzfeldt-Jakob disease: A case-control study. Ann Neurol 59: 111-120.
87. Ward HJ, Everington D, Cousens SN, Smith-Bathgate B, Gillies M, Murray K, Knight RS, Smith PG, Will RG. 2008. Risk factors for sporadic Creutzfeldt-Jakob disease. Ann Neurol 63: 347-354.
88. Will RG. 2002. Clinical features of human prion diseases. In Diseases of the nervous system, 3rd ed. (ed. Asbury AK, et al.) pp. 1716-1727. CambridgeUniversity Press, Cambridge.
89. Will B. 2010. Variant CJD: Where has it gone, or has it? Pract Neurol 10: 250-251.
90. Will RG. 2014. Prions and agents of TSEs. In Encyclopedia of food safety, Vol. 2, pp. 12-17. Elsevier, Amsterdam.
91. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG. 1996. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347: 921-925.
92. Yamada M. 2006. The first Japanese case of variant Creutzfeldt-Jakob disease showing periodic electroencephalogram. Lancet 367: 874.
93. Yamada M, Noguchi-Shinohara M, Hamagucchi T, Nozaki I, Kitamoto T, Sato T, Nakamura Y, Mizusawa H. 2009. Dura mater graft-associated Creutzfeldt-Jakob disease in Japan: Clinicopathological and molecular characterization of the two distinct subtypes. Neuropathology 29: 609-618.
94. Zeidler M, Johnstone EC, Bamber RW, Dickens CM, Fisher CJ, Francis AF, Goldbeck R, Higgo R, Johnson-Sabine EC, Lodge GJ, et al. 1997a. New variant Creutzfeldt-Jakob disease: Psychiatric features. Lancet 350: 908-910.
95. Zeidler M, Stewart GE, Barraclough CR, Bateman DE, Bates D, Burn DJ, Colchester AC, Durward W, Fletcher NA, Hawkins SA, et al. 1997b. New variant Creutzfeldt-Jakob disease: Neurological features and diagnostic tests. Lancet 350: 903-907.
96. Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro Cuesta J, Knight RS, Bernheimer H, Cardone F, Delasnerie-Laupretre N, Cuadrado Corrales N, et al. 2000. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 55: 811-815.
97. Zou WQ, Puoti G, Xiao X, Yuan J, Qing L, Cali I, Shimoji M, Langeveld JP, Castellani R, Notari S, et al. 2010. Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein. Ann Neurol 68: 162-172.